

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/002070-2023>

Planning

MHRA specials licenced manufacturing facility

Northumbria Healthcare NHS Foundation Trust

F01: Prior information notice

Prior information only

Notice identifier: 2023/S 000-002070

Procurement identifier (OCID): ocds-h6vhtk-0399ed

Published 23 January 2023, 5:59pm

Section I: Contracting authority

I.1) Name and addresses

Northumbria Healthcare NHS Foundation Trust

Northumbria House, Unit 7/8 Silverfox Way

Newcastle Upon Tyne

NE27 0QJ

Contact

Mr Kevin Marshall

Email

kevin.marshall@northumbria-healthcare.nhs.uk

Telephone

+44 150129

Country

United Kingdom

Region code

UKC - North East (England)

Internet address(es)

Main address

<https://www.northumbria.nhs.uk>

Buyer's address

<https://www.northumbria.nhs.uk>

I.3) Communication

Access to the procurement documents is restricted. Further information can be obtained at

<https://procontract.due-north.com>

Additional information can be obtained from the above-mentioned address

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

MHRA specials licenced manufacturing facility

Reference number

DN652731

II.1.2) Main CPV code

- 33000000 - Medical equipments, pharmaceuticals and personal care products

II.1.3) Type of contract

Supplies

II.1.4) Short description

The North East and North Cumbria (NENC) Provider Collaborative is a formal partnership of all 11 NHS Foundation Trusts (FTs) in the region. Together it covers the entire geographical footprint of the NENC Integrated Care System, from North Yorkshire up to the Scottish borders, and provides the vast majority of all secondary NHS care services with millions of patient interactions every single day.

The NENC Provider Collaborative proposes in this pre market engagement document is to establish a NENC aseptic pharmaceutical production hub at Seaton Delaval, as part of a hub and spoke model, with four initial key priority areas:

1. Injectable chemotherapy medicines supply
2. Addressing nursing time currently spent preparing injectable medicines (primarily Ready to Administer (RtA) injectable antibiotic medicines to clinical areas)
3. Parenteral nutrition production
4. Provision of centralised over labelling of medicines

This will deliver substantial benefits improving clinical safety, delivering a reliable supply of products for patient use, freeing up capacity on hospital sites and directly releasing significant nursing time for patient care.

NENC PC are looking to assess the feasibility of establishing an MHRA specials licenced manufacturing facility capable of meeting GMP, quality and operational requirements.

The proposed output of this facility will be:

- 950,000 Ready to Administer (RtA) products
- 70,000 Systemic anti-cancer therapies and Monoclonal antibodies
- 70,000 Parenteral Nutrition products.
- 400,000 - 600,000 over labelled products.

NHFM is conducting a preliminary market consultation in accordance with the Public Contracts Regulations 2015 reg. 40 with interested organisations to be held on the 10th and 14th February 2023 details of which can be downloaded from the NHFM e-tender Portal <https://procontract.due-north.com> reference number DN652731

Following the event companies will be required to complete a questionnaire which must be returned via the NHFM e tender portal no later than 12:00 Noon on 24/2/23.

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.3) Place of performance

NUTS codes

- UKC - North East (England)

Main site or place of performance

The intended location of the facility is the North East and North Cumbria Manufacturing Facility, Northumbria Healthcare NHS manufacturing and innovation hub, Seaton Delaval, Northumberland.

II.2.4) Description of the procurement

The NENC PC are looking to assess the feasibility of establishing an MHRA specials licenced manufacturing facility capable of meeting GMP, quality and operational requirements.

The proposed output of this facility will be:

- 950,000 Ready to Administer (RtA) products
- 70,000 Systemic anti-cancer therapies and Monoclonal antibodies
- 70,000 Parenteral Nutrition products.
- 400,000 - 600,000 over labelled products.

II.3) Estimated date of publication of contract notice

1 May 2023

Section IV. Procedure

IV.1) Description

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes